Picture of Bavarian Nordic A/S logo

BAVA — Bavarian Nordic A/S News Story

0.000.00%
dk flag iconLast trade - 00:00
HealthcareSpeculativeMid CapNeutral

Bavarian Nordic beats Q3 revenue expectations on travel health strength (updated)

UPDATE 1-Bavarian Nordic beats Q3 revenue expectations on travel health strength

Adds CFO comments in paragraph 2, bullet point 3; US demand for rabies vaccine in bullet point 2

- Danish vaccine maker Bavarian Nordic BAVA.CO reported better-than-expected third-quarter revenue on Friday, boosted by a continued strong performance in its travel health business.

CFO Henrik Juuel told Reuters Bavarian does not see any signs that the market for the rabies vaccine - one of its biggest revenue drivers - will decline anytime soon.

  • Travel health revenue rose 22%, beating consensus by 13%, driven by the continued strong sales of its rabies vaccines RabAvert/Rabipur and supported by the continued launch of its chikungunya vaccine Vimkunya

  • The US rabies vaccine market grew by 36% in the first nine months versus the prior year

  • Juuel said the awareness around the disease was encouraging more people to seek vaccination

  • Third-quarter revenue of 1.81 billion Danish crowns ($267.81 million) beat analysts' average consensus estimate of 1.69 billion

  • The company reiterated the full-year guidance it upgraded in October



($1 = 6.7585 Danish crowns)


(Reporting by Elviira Luoma, editing by Matt Scuffham and Anna Pruchnicka)

((elviira.luoma@thomsonreuters.com; +48 58 769 66 46;))

Recent news on Bavarian Nordic A/S

See all news